PRKAA1 and ovarian carcinoma: Although the clinical benefit of the AMPK activation-mediated targeted therapy with a combined cocktail of lipid metabolic modulators is still reticently reported, the innovative idea proposed herein may recommend the feasibility of this alternative therapeutic intervention to impede ovarian cancer peritoneal metastases.